ArticleBioEssays : news and reviews in molecular, cellular and developmental biology2011
In defense of the somatic mutation theory of cancer.
Article in BioEssays : news and reviews in molecular, cellular and developmental biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 97 citations in OpenAlex.
- The end of the genetic paradigm of cancer.PLoS biology · 2025Review
- Initiation of Cancer: The Journey From Mutations in Somatic Cells to Epigenetic Changes in Tissue-resident VSELs.Stem cell reviews and reports · 2024Review
- Microbes, macrophages, and melanin: a unifying theory of disease as exemplified by cancer.Frontiers in immunology · 2024Review
- Stem cell mutations, associated cancer risk, and consequences for regenerative medicine.Cell stem cell · 2023Review
- The essential molecular requirements for the transformation of normal cells into established cancer cells, with implications for a novel anti-cancer agent.Cancer reports (Hoboken, N.J.) · 2023Review
- Glioblastoma CD105Acta neuropathologica communications · 2022Article
- Review
- Why Do We Care More About Disease than Health?Phenomics (Cham, Switzerland) · 2022Article
- Bioelectric Dysregulation in Cancer Initiation, Promotion, and Progression.Frontiers in oncology · 2022Review
- Cancer progression as a sequence of atavistic reversions.BioEssays : news and reviews in molecular, cellular and developmental biology · 2021Article
- A bioelectric model of carcinogenesis, including propagation of cell membrane depolarization and reversal therapies.Scientific reports · 2021Article
- Cell Reversal From a Differentiated to a Stem-Like State at Cancer Initiation.Frontiers in oncology · 2020Article
- Review
- A Postgenomic Perspective on Molecular Cytogenetics.Current genomics · 2018Article
- Changing mutational and adaptive landscapes and the genesis of cancer.Biochimica et biophysica acta. Reviews on cancer · 2017Review
- Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer.Biochimica et biophysica acta. Reviews on cancer · 2017Review
- Dynamics inside the cancer cell attractor reveal cell heterogeneity, limits of stability, and escape.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Reasons for cancer metastasis: A holistic perspective.Molecular and clinical oncology · 2015Article
- Cancer as a mitochondrial metabolic disease.Frontiers in cell and developmental biology · 2015Article
- Competing views on cancer.Journal of biosciences · 2014Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to the somatic mutation theory (SMT), cancer begins with a genetic change in a single cell that passes it on to its progeny, thereby generating a clone of malignant cells. It is strongly supported by observations of leukemias that bear specific chromosome translocations, such as Burkitt's lymphoma, in which a translocation activates the c-myc gene, and chronic myeloid leukemia (CML), in which the Philadelphia chromosome causes production of the BCR-ABL oncoprotein. Although the SMT has been modified and extended to encompass tumor suppressor genes, epigenetic inheritance, and tumor progression through accumulation of further mutations, perhaps the strongest validation comes from the successful treatment of certain malignancies with drugs that directly target the product of the mutant gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.